Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: The potential value of prognostic molecular markers

Gabrielle Jongeneel*, Marjolein J.E. Greuter, Natalia Kunst, Felice N. Van Erning, Miriam Koopman, Jan P. Medema, Louis Vermeulen, Jan N.M. Ijzermans, Geraldine R. Vink, Cornelis J.A. Punt, Veerle M.H. Coupé

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: The potential value of prognostic molecular markers'. Together they form a unique fingerprint.

Medicine & Life Sciences